TYK Medicines (HKSE:02410) Total Operating Expense: HK$324.94 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02410 TYK Medicines Inc HKSE:02410
7 GF Score
Price HK$6.81
! 3 Warning Signs
View Full Analysis

What is TYK Medicines Total Operating Expense?

TYK Medicines HKSE:02410 -4.08% 7 Total Operating Expense is HK$324.94 Mil as of Dec. 2025. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

TYK Medicines's Total Operating Expense for the six months ended in Dec. 2025 was HK$203.67 Mil. TYK Medicines's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$324.94 Mil.

TYK Medicines Total Operating Expense Related Terms

TYK Medicines Total Operating Expense Historical Data

* Premium members only.

The historical data trend for TYK Medicines's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TYK Medicines Total Operating Expense Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
284.58 313.08 338.25 326.23

TYK Medicines Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial 166.64 180.87 158.88 121.27 203.67
HKSE:02410
7GF Score
TYK Medicines Inc HKSE:02410
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TYK Medicines Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$324.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of HK$324.94 Mil mean?
TYK Medicines (HKSE:02410) has a Total Operating Expense of HK$324.94 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on TYK Medicines and its competitors.
Is TYK Medicines' Total Operating Expense too high?
TYK Medicines' current Total Operating Expense is HK$324.94 Mil. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' Total Operating Expense compare to VRTX and REGN?
TYK Medicines' Total Operating Expense of HK$324.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on TYK Medicines and its competitors. TYK Medicines's current Total Operating Expense is HK$324.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current Total Operating Expense of HK$324.94 Mil. The current Total Operating Expense is HK$324.94 Mil. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current Total Operating Expense is HK$324.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TYK Medicines Business Description

Address No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score

Get the complete analysis for HKSE:02410

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.81
Price